On February 15, 2024, Windtree Therapeutics, Inc. and John A. Tattory mutually agreed to Mr. Tattory?s resignation from his positions as the Interim Chief Financial Officer and principal financial officer of the Company, effective February 15, 2024. Mr. Tattory?s resignation is the result of a mutual decision between Mr. Tattory and the Company relating to certain cost-cutting measures the Company is implementing, and is not related to any disagreement or dispute with the Company or its Board of Directors on any matter, including the Company?s accounting principles, practices, financial statement disclosures or compliance procedures. Craig E. Fraser, who currently serves as the Company?s President, Chief Executive Officer and Chairman of the Board of Directors, will assume the responsibilities of principal financial officer for purposes of the Securities Exchange Act of 1934, as amended, on an interim basis.

Mr. Tattory will continue to provide his services to the Company as a consultant through LifeSci Associates, a business unit of LifeSci Advisors, LLC, at an agreed upon hourly rate.